This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Janssen-Cilag, Germany.
Reference
Mahlich J, et al. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis. Advances in Therapy : 17 May 2019. Available from: URL: http://doi.org/10.1007/s12325-019-00969-8
Rights and permissions
About this article
Cite this article
Treatment persistence rates high with ustekinumab in psoriasis. PharmacoEcon Outcomes News 829, 30 (2019). https://doi.org/10.1007/s40274-019-5944-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5944-0